Welcome to our dedicated page for Processa Pharmaceuticals news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals stock.
Processa Pharmaceuticals, Inc. (symbol: PCSA) is a clinical-stage biopharmaceutical company, founded in October 2017 and headquartered in Hanover, Maryland. The company's mission is to develop products that can significantly improve the survival and quality of life for patients with high unmet medical needs, particularly in the field of oncology.
Processa Pharmaceuticals specializes in the development of Next Generation Chemotherapy (NGC) oncology drug products using a unique 'regulatory science' approach. The company's primary focus is to advance its pipeline of proprietary small molecule oncology drugs. These NGC products are new chemical entities designed to alter the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites, while preserving the original mechanisms of action that kill cancer cells.
The company's current pipeline includes three promising NGC treatments:
- NGC-Capecitabine (NGC-Cap): This therapy involves Capecitabine administered with PCS6422, aiming to enhance efficacy and reduce side effects.
- PCS3117 (NGC-Gemcitabine or NGC-Gem): A novel formulation intended to improve the therapeutic profile of Gemcitabine.
- PCS11T (NGC-Irinotecan or NGC-Iri): Another innovative treatment designed to optimize the benefits of Irinotecan.
Processa Pharmaceuticals is committed to leveraging its expertise in regulatory science to bring these next-generation treatments to market. The company's strategic partnerships and ongoing clinical trials play a crucial role in advancing its mission and providing hope to patients battling cancer. For the latest updates and more information, investors can contact Patrick Lin at plin@processapharma.com.
Processa Pharmaceuticals has announced positive results from their Phase 1b trial of NGC-Cap in gastrointestinal cancer patients. The trial involved 12 patients, with 66.7% achieving progression-free survival (PFS) ranging from 5 to 11 months. At the highest dose, all patients showed PFS, with two partial responses and one stable disease. Compared to monotherapy capecitabine, 5-FU exposure was greater, and FBAL exposure was lower, with better or similar side effects. These promising results support further development, with a Phase 2 trial in breast cancer slated for the third quarter of 2024.
Processa Pharmaceuticals, Inc. (PCSA) will participate in the EF Hutton Annual Global Conference on May 15, 2024, in New York City. The company aims to develop advanced chemotherapeutic drugs for improved efficacy and safety.
Processa Pharmaceuticals, Inc. appointed Dr. Steven Cha as Senior Vice President of Clinical Research. Dr. Cha brings extensive experience in oncology drug development, having guided multiple oncology therapies through all phases of development, including regulatory approval and commercialization. His leadership will be important as Processa advances its oncology programs, with plans to initiate a Phase 2 trial in breast cancer.
FAQ
What is the current stock price of Processa Pharmaceuticals (PCSA)?
What is the market cap of Processa Pharmaceuticals (PCSA)?
What is Processa Pharmaceuticals, Inc.?
When was Processa Pharmaceuticals founded?
Where is Processa Pharmaceuticals headquartered?
What is the mission of Processa Pharmaceuticals?
What does NGC stand for?
What are the main products in Processa Pharmaceuticals' pipeline?
What is the unique approach of Processa Pharmaceuticals?
How can investors get more information about Processa Pharmaceuticals?
What recent achievements has Processa Pharmaceuticals made?
Does Processa Pharmaceuticals have any partnerships?
